Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Mechanisms of mutations in myeloproliferative neoplasms.

Levine RL.

Best Pract Res Clin Haematol. 2009 Dec;22(4):489-94. doi: 10.1016/j.beha.2009.08.006. Review.

PMID:
19959098
2.

Molecular aspects of myeloproliferative neoplasms.

Delhommeau F, Jeziorowska D, Marzac C, Casadevall N.

Int J Hematol. 2010 Mar;91(2):165-73. doi: 10.1007/s12185-010-0530-z. Epub 2010 Feb 27. Review.

PMID:
20186505
3.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
4.

The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.

Zhang SJ, Qiu HX, Li JY, Shi JY, Xu W.

Int J Lab Hematol. 2010 Aug 1;32(4):381-6. doi: 10.1111/j.1751-553X.2009.01208.x. Epub 2010 Mar 23.

PMID:
20331763
5.

JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.

PMID:
18032973
6.

Janus kinase mutations.

Levine RL.

Semin Oncol. 2009 Apr;36(2 Suppl 1):S6-11. doi: 10.1053/j.seminoncol.2009.02.005.

PMID:
19393837
7.

JAK-2 mutations and their relevance to myeloproliferative disease.

Levine RL, Gilliland DG.

Curr Opin Hematol. 2007 Jan;14(1):43-7. Review.

PMID:
17133099
8.

Genetics of the myeloproliferative neoplasms.

Abdel-Wahab O.

Curr Opin Hematol. 2011 Mar;18(2):117-23. doi: 10.1097/MOH.0b013e328343998e. Review.

PMID:
21307773
9.

Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.

Koh SP, Yip SP, Lee KK, Chan CC, Lau SM, Kho CS, Lau CK, Lin SY, Lau YM, Wong LG, Au KL, Wong KF, Chu RW, Yu PH, Chow EY, Leung KF, Tsoi WC, Yung BY.

BMC Genet. 2014 Dec 20;15:147. doi: 10.1186/s12863-014-0147-y.

10.

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?

James C.

Hematology Am Soc Hematol Educ Program. 2008:69-75. doi: 10.1182/asheducation-2008.1.69. Review.

PMID:
19074061
11.

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B.

Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.

PMID:
21904853
12.

Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.

Chen X, Qi X, Tan Y, Xu Z, Xu A, Zhang L, Wang H.

Blood Cells Mol Dis. 2011 Jun 15;47(1):67-71. doi: 10.1016/j.bcmd.2011.04.004. Epub 2011 May 8.

PMID:
21555228
13.

Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms.

dos Santos MT, Mitne-Neto M, Miyashiro K, Chauffaille Mde L, Rizzatti EG.

J Clin Pathol. 2014 Feb;67(2):176-8. doi: 10.1136/jclinpath-2013-201822. Epub 2013 Aug 28.

14.

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.

PMID:
17124066
15.

JAK2 and MPL mutations in myeloproliferative neoplasms.

Koppikar P, Levine RL.

Acta Haematol. 2008;119(4):218-25. doi: 10.1159/000140634. Epub 2008 Jun 20. Review.

PMID:
18566540
16.

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

Levine RL, Pardanani A, Tefferi A, Gilliland DG.

Nat Rev Cancer. 2007 Sep;7(9):673-83. Review.

PMID:
17721432
17.

JAK2V617F mutations in myeloid malignancies: single center experience.

Panovska-Stavridis I, Cevreska L, Ivanovski M, Stojanovik A, Lozance M, Matevska N, Dimovski A, Serafimoski V.

Prilozi. 2008 Dec;29(2):257-67.

PMID:
19259051
18.

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.

Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pascutto C, Berg T, Jäger R, Hammond E, Cazzola M, Kralovics R.

Haematologica. 2011 Mar;96(3):367-74. doi: 10.3324/haematol.2010.034488. Epub 2010 Dec 20.

19.

Genotype-phenotype interactions in the myeloproliferative neoplasms.

Godfrey AL, Green AR.

Hematol Oncol Clin North Am. 2012 Oct;26(5):993-1015. doi: 10.1016/j.hoc.2012.07.003. Epub 2012 Aug 28. Review.

PMID:
23009934
20.

The spectrum of JAK2-positive myeloproliferative neoplasms.

Kiladjian JJ.

Hematology Am Soc Hematol Educ Program. 2012;2012:561-6. doi: 10.1182/asheducation-2012.1.561. Review.

PMID:
23233635
Items per page

Supplemental Content

Write to the Help Desk